Our Pipeline

Looking Ahead

Groundbreaking pharmaceuticals for treating
CNS-related conditions

Based on the expertise and commitment of our R&D and management teams, Neurim’s in-depth understanding of the Central Nervous System enables us to realize the clinical potential of pharmaceutical formulations that address crucial unmet patient needs in significant markets. Our efforts are reinforced by fruitful collaborations with academic and independent research institutes and contract research organizations.

Prolonged release Melatonin
Research
Preclinical
Phase I
Phase II
Phase III
Marketing
Primary Insomnia in adults age 55 or over
R
P
P1
P2
P3
M
Pediatric prolonged release Melatonin
Research
Preclinical
Phase I
Phase II
Phase III
Marketing
Pediatric Insomnia in Autism Spectrum Disorder, Neurogenetic Disorders and Attention-Deficit Hyperactivity Disorder
R
P
P1
P2
P3
M
Piromelatine
PRODUCT CANDIDATE
Research
Preclinical
Phase I
Phase II
Phase III
Marketing
iRBD
R
P
P1
P2
P3
M
More information

More Information Will Be Added Soon 

Gal-475
PRODUCT CANDIDATE
Research
Preclinical
Phase I
Phase II
Phase III
Marketing
Weight Loss
R
P
P1
P2
P3
M
More information

More Information Will Be Added Soon 

Neurim Pharmaceuticals’ strategic focus is on expanding its development pipeline by partnering, as
well as by acquiring and licensing clinical-stage assets.